The United Kingdom and the United States have announced a important commercial pact that will ensure zero tariffs on British pharmaceutical shipments going into the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase funding on drugs through the NHS. This commitment ensures that duties on these key exports will be held at zero for a duration of 36 months.
This agreement comes after recent threats to dramatically increase duties on branded drug imports, with increases discussed reaching double the cost.
"This deal between the Britain strengthens the worldwide climate for new treatments and brings long-overdue fairness to U.S.–U.K. drug exports," an announcement said.
Commercial Importance
Medicines constitute one of the the United Kingdom's largest exports to the United States, which is easily the largest destination for leading companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period to the end of September, the UK exported pharmaceutical products valued at billions to the US. This amount accounted for a significant portion of British export trade in that span.
"This agreement protects employment, stimulates funding and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Key NHS Changes
The deal entails several specific pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to double total health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage drug companies must pay back to the NHS to prevent overspending will be limited at 15%. Previously, refunds were more than 20%.
Broader Context
The deal comes amid a long-running dispute between the sector and the British authorities over medicine costs and regulatory access.
The disagreement were exacerbated by assertions that American consumers were charged significantly more for the equivalent treatments than people in the UK and Europe.
In recent months, several major drug company projects in the UK have been delayed or scrapped, while major investments have been announced toward US facilities.
A senior figure acknowledged that the NHS needed to spend more on medicines, noting that its spending on drugs had declined as a share of its resources over the past decade.
